AstraZeneca (LSE:AZN) Advances Cancer Drug In EU With EMA Application Validation

AstraZeneca (LSE:AZN) recently saw its stock price increase by 9% over the last quarter, a move potentially influenced by the European Medicines Agency's validation of its ENHERTU® marketing authorization application. This development complements other significant news, such as the favorable TAGRISSO trial results and regulatory approvals for DATROWAY, which could have added positive momentum. Amid these corporate achievements, broader market trends saw the Nasdaq hitting new highs, reflecting a buoyant tech sector, while inflation data hinted at impending rate cuts from the Federal Reserve. Overall, AstraZeneca’s recent performance aligns with a generally positive market movement.

We've spotted 3 weaknesses for AstraZeneca you should be aware of.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

The recent developments including the European Medicines Agency's validation for AstraZeneca’s ENHERTU® application and favorable trial results for TAGRISSO may reinforce the company's existing narrative of leveraging a robust late-stage pipeline. These advancements could potentially accelerate AstraZeneca's projected revenue growth, especially in oncology, positioning it to capture heightened demand in emerging markets. If these drugs meet expectations, they may contribute significantly to future earnings, enhancing shareholder value and justifying analysts' optimistic revenue forecasts.

Looking at the longer-term context, AstraZeneca's shares have yielded a total return of 55.04% over the past five years, reflecting the company's solid execution of its business strategies. In the past year, the stock outperformed the UK Pharmaceuticals industry, which saw returns at -3.2%, showcasing a strong relative performance. However, it underperformed the broader UK Market, which returned 11.5%, indicating room for improvement in the market-wide context.

The stock's current price of £119.56 reveals a discount of around 14% to the consensus analyst price target of £136.57. This suggests potential upside if the company meets analyst expectations for earnings and revenue by 2028, as detailed in their forecasts. However, investors should balance this with caution about external challenges, including regulatory risks and competitive pressures, which could alter the trajectory of future returns.

Our valuation report unveils the possibility AstraZeneca's shares may be trading at a discount.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com